Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults
Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults
Ascendis Pharma的YORVIPATH现在在美国正式推出，用于治疗成人低甲状旁腺功能减退症。
Ascendis Pharma A/S (NASDAQ:ASND) today announced that YORVIPATH (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once-daily, designed to provide continuous exposure to active PTH over the 24-hour dosing period. It is the first and only medicine approved by the U.S. Food & Drug Administration (FDA) for the treatment of hypoparathyroidism in adults.
Ascendis Pharma A/S（纳斯达克:ASND）今日宣布，YORVIPATH（帕洛帕肽；开发作为TransCon PTH）现在在美国可以通过处方获得。YORVIPATH是甲状旁腺激素（PTH [1-34]）的前药，按需每日一次给药，旨在提供对活性PTH的持续暴露，覆盖24小时的给药周期。它是美国食品和药物管理局（FDA）批准的第一个也是唯一一个用于治疗成人低甲状旁腺激素症的药物。